Table II.
Immunohistochemical subtypes distribution.
| Characteristic | Luminal, n (%) | Luminal-HER2, n (%) | HER2, n (%) | Triple-negative, n (%) | P-value |
|---|---|---|---|---|---|
| Total | 159 (100.0) | 28 (100.0) | 57 (100.0) | 49 (100.0) | |
| Age, years | |||||
| Median | 53 | 51 | 55 | 55 | |
| Range | 28–84 | 33–83 | 34–74 | 29–84 | |
| Age distribution | 0.155 | ||||
| <50 years | 70 (44.0) | 10 (35.7) | 17 (29.8) | 15 (30.6) | |
| ≥50 years | 89 (56.0) | 18 (64.3) | 40 (70.2) | 34 (69.4) | |
| Status | 0.133 | ||||
| Stage IV | 42 (26.4) | 13 (46.4) | 21 (36.8) | 16 (32.7) | |
| Recurrence | 117 (73.6) | 15 (53.6) | 36 (63.2) | 33 (67.3) | |
| DFI, days | 1,766 | 1,293 | 769 | 694 | |
| No. of metastases, n | |||||
| Median | 2.3 | 2.8 | 3.1 | 4.0 | |
| Range | 1–6 | 1–8 | 1–7 | 1–7 | |
| Site of metastasis | 0.016 | ||||
| Lymph node | 96 (60.4) | 18 (64.3) | 40 (70.2) | 36 (73.5) | |
| Liver | 80 (50.3) | 12 (42.9) | 25 (43.9) | 21 (42.9) | |
| Lung | 80 (50.3) | 11 (39.3) | 33 (57.9) | 32 (65.3) | |
| Bone | 114 (71.7) | 15 (53.6) | 24 (42.1) | 25 (51.0) | |
| Brain | 22 (13.8) | 5 (17.9) | 22 (38.6) | 20 (40.8) | |
| Local | 28 (17.6) | 4 (14.3) | 14 (24.6) | 18 (36.7) | |
| Other | 26 (16.4) | 5 (17.9) | 8 (14.0) | 12 (24.5) | |
| No. of chemotherapy regimens | 0.003 | ||||
| None | 21 (13.2) | 8 (28.6) | 20 (35.1) | 16 (32.7) | |
| 1 | 55 (34.6) | 9 (32.1) | 19 (33.3) | 20 (40.8) | |
| 2 | 39 (24.5) | 9 (32.1) | 12 (21.1) | 10 (21.4) | |
| 3 | 26 (16.4) | 1 (3.6) | 4 (7.0) | 1 (2.0) | |
| ≥4 | 18 (11.3) | 1 (3.6) | 2 (3.5) | 2 (4.1) | |
| Prior anthracycline administration | <0.001 | ||||
| For metastasis | 90 (56.6) | 8 (28.6) | 24 (42.1) | 17 (34.7) | |
| NAC or adjuvant | 34 (21.4) | 1 (3.6) | 0 (0.0) | 3 (6.1) | |
| Chemotherapy regimen | |||||
| Weekly Paclitaxel | 94 (59.1) | 22 (78.6) | 47 (82.5) | 27 (55.1) | |
| Triweekly Docetaxel | 65 (40.9) | 6 (21.4) | 10 (17.5) | 22 (44.9) | |
| With Trastuzumab | 3 (1.9) | 25 (89.3) | 54 (94.7) | 0 (0.0) |
DFI, disease free interval (median); NAC, neoadjuvant chemotherapy; HER2, human epidermal growth factor receptor type 2.